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Liver failure is still a significant clinical problem after transplantation surgery,
tissue resections (the Pringle manoeuvre) and haemorrhagic shock. The resto-
ration of blood flow to an ischaemic region leads to tissue injury at a greater
rate than the original ischaemic insult, an event termed “ischaemia-reperfusion
injury” (I/R). Despite advances in surgical techniques, I/R still poses a problem
of clinical importance. In this research, we studied the effect of simvastatin
pretreatment on liver and lung injury induced by hepatic I/R.
Rats were subjected to 30 min of ischaemia followed by 24 h of reperfusion.
Simvastatin (10 mg/kg) was administered orally from three days before the
operation. After the reperfusion time, serum ALT, AST, LDH and TNFa levels
were studied and liver and lung tissues were stained with haematoxylin and
eosin and TUNEL to detect apoptotic cells.
Serum aminotransferase activity and LDH and TNFa levels were increased mark-
edly by hepatic I/R, and these were suppressed significantly by simvastatin. The
tissue injury index and the number of apoptotic cells via TUNEL staining in the
liver and lungs were higher in the I/R group than in the I/R + simvastatin group.
These results suggest that simvastatin ameliorates I/R-induced liver and lung tis-
sue damage by inhibiting the level of inflammation and the apoptotic pathways.
Simvastatin administration may therefore provide protection against the adverse
effects of I/R injury in liver transplantation. (Folia Morphol 2008; 67: 231–235)
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INTRODUCTION
Liver failure is still a significant clinical problem
after transplantation surgery, tissue resections (the
Pringle manoeuvre) and haemorrhagic shock [10, 17,
19, 30]. The restoration of blood flow to an ischaemic
region leads to tissue injury at a greater rate than
the original ischaemic insult, an event termed
“ischaemia-reperfusion injury” (I/R). Although the
exact mechanisms involved in the pathogenesis of
hepatic I/R injury have not been fully elucidated, it
is generally believed that activated Kupffer cells re-
lease reactive oxygen species, nitric oxide and sever-
al proinflammatory cytokines. These cytokines, to-
gether with the increased expression of adhesion
molecules by sinusoidal endothelial cells, promote
liver neutrophil infiltration, thus contributing to the
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progression of parenchymal injury [6, 7, 12, 13, 18].
Efforts to attenuate I/R injury have been focused
on blocking the events associated with irreversible
liver damage. Hepatic I/R, in addition to liver inju-
ry, induces remote organ injury, especially in lung
tissue [14]. Pharmacological preconditioning in-
cludes blocking the injury process, mainly the oxi-
dative and inflammatory pathways, by drug admin-
istration.
Statins are a class of compound that competi-
tively inhibit the enzyme 3-hydroxy-3-methylglutar-
yl coenzyme A (HMG-CoA) reductase, the first com-
mitted step in cholesterol biosynthesis.
Statins can be classified into three categories: nat-
urally derived (lovastatin and pravastatin), semisynthet-
ic (simvastatin), and synthetic (atorvastatin, fluvasta-
tin, cerivastatin, rosuvastatin, and pitavastatin) [22].
It has been shown that statins that contain a lactone
structure with high lipophilic properties, that is, sim-
vastatin and lovastatin, exhibit a potent vasodilatory
effect in the intact heart [8] and in vessels isolated
from various tissues [1, 2, 21, 24, 28]. Increasingly,
the pleiotropic properties of statins are being de-
scribed. In endothelial cells, all of these effects seem
to result from the inhibition of cholesterol’s precursor,
mevalonic acid, which is critical to the isoprenylation
of a diverse family of proteins [3, 5]. Simvastatin,
a HMG-CoA reductase inhibitor, has been shown to
exhibit important immunomodulatory effects indepen-
dent of lipid lowering [15]. These pleiotropic effects
have been demonstrated to include anti-inflammato-
ry actions [27], improvement of endothelial and mi-
crovascular function, modulation of endothelial nitric
oxide synthase (eNOS) [16], ischaemia/reperfusion [25]
and sepsis [23]. However, the effect of statins has not
been studied in hepatic I/R injury.
MATERIAL AND METHODS
Animals
Forty-five male Wistar rats were divided into three
groups. Group 1, the sham group, underwent
laparatomy but did not experience I/R; group 2, the
I/R group, underwent ischaemia for 30 min and were
reperfused for 24 h; Group 3 underwent ischaemia
and reperfusion like group 2 but also received
10 mg/kg simvastatin dissolved in water by oral gav-
age for three days before the operation.
All the animals had access to water and rat chow
ad libitum before, during, and after the ischaemia.
The animals were maintained in accordance with the
Guide for the Care and Use of Laboratory Animals
prepared by the National Academy of Sciences and
published by the National Institutes of Health (NIH
publication 86-23, revised 1985).
Induction of ischaemia
Briefly, the anterior abdominal wall was shaved
and prepared with povidone-iodine solution. The
abdomen was entered through a midline incision
under ether anaesthesia and ischaemia was induced
by occluding the blood vessels, including the bile
duct, with an atraumatic vascular clamp. As a mod-
el for acute experiments, 30 min ischaemia of the
liver lobe was performed by clamping the portal vein,
hepatic artery and bile duct origin. Reperfusion was
initiated by removal of the clamp and the abdomen
was closed in two layers with 2-0 silk. Thereafter
the abdominal cavity was closed with running su-
tures and the animals were allowed to awaken with-
out resuscitation by additional fluid. The animals had
free access to water and rat chow ad libitum. After
24 h of reperfusion the anaesthetised animals were
sacrificed and liver and lung tissue and plasma were
stored for further examination.
Histological analysis
Excised liver specimens were fixed in 4% PBS-
-buffered paraformaldehyde and embedded in par-
affin. Five-micrometre liver sections stained with
haematoxylin and eosin were evaluated at × 200
magnification by a point-counting method for the
severity of hepatic injury.
In situ detection of apoptotic cells
Serial sections of 4-mm thickness were prepared.
TUNEL staining was performed with the use of an in
situ apoptosis detection kit according to the manu-
facturer’s instruction (Boehringer Mannheim, Ger-
many) and examined by light microscopy. The apo-
ptotic index (AI) was calculated as the percentage
of stained cells, namely: AI = number of apoptotic
cells in 100/total number of nucleated cells.
The histopathological scoring analysis was per-
formed according to previously described methods
with modifications. For liver and lungs the assess-
ment was expressed as the sum of the individual
score grades from 0 (no findings), 1 (mild), 2 (mod-
erate) to 3 (severe) for each of the following six pa-
rameters from the liver sections: cytoplasmatic co-
lour fading, vacuolisation, nuclear condensation,
nuclear fragmentation, nuclear fading and erythro-
cyte stasis, or for six parameters from the lung sec-
tions: interstitial oedema, alveolar oedema, alveolar
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haemorrhage, atelectasis, inflammatory cellular in-
filtration and pulmonary congestion [9, 32].
Biochemical analysis
Blood samples were collected. Serum was ob-
tained by centrifugation. Samples were stored at
–20oC until analysis. TNFa, ALT, AST, and LDH levels
were determined by commercial kits.
Statistical analysis
Mean standard error of the mean (SEM) values
for various groups were compared using Fisher’s
exact test, analysis of variance (ANOVA) or ANOVA
on ranks, as appropriate, with p < 0.05 selected
prior to the study as the criterion for significance of
differences between groups.
RESULTS
Liver function
We examined the serum activities of AST and
ALT as markers of liver function at 24 h after I/R.
The activities of AST, ALT and LDH in the I/R group
were markedly increased, compared with the SHAM
or I/R + simvastatin group (Table 1).
Tumour necrosis factor a
The level of TNFa was increased in the I/R group.
This increase was significantly diminished by prior
simvastatin treatment in the I/R + simvastatin group
(Table 1).
Analysis by the TUNEL method of apoptosis in
the liver and lung tissue showed that the apoptosis
index was significantly lower in the simvastatin + I/R
group than in the I/R group. Very few TUNEL-posi-
tive hepatocytes were detected in the sham groups
(Table 2).
Tissue morphology
In the liver and lung tissue no significant chang-
es were found in the sham group at light microsco-
py. At 24 h after reperfusion extensive karyopycno-
sis, severe necrosis and loss of intercellular borders
were seen in the I/R group. At these time points hepa-
tocyte damage was slighter in the simvastatin treat-
ment group than in the I/R group (Table 2). These
results indicated that hepatic injury induced by
I/R was much more severe in the I/R group than in
the C + I/R group. Moreover, in the lungs tissue in-
jury, including interstitial oedema, alveolar oedema,
alveolar haemorrhage, atelectasis, inflammatory cel-
lular infiltration and pulmonary congestion, in the
I/R group was significantly more severe than in the
I/R + simvastatin group (Table 2).
DISCUSSION
In this study, we have demonstrated that simv-
astatin pretreatment afforded functional and histo-
logic hepatic and lung protection in hepatic I/R in-
ducted injury in rats, and this was accompanied by
suppression of TNFa production and subsequent
Table 1. Serum activities of ALT, AST, LDH and TNFa measured in rats 24 h after reperfusion. Results expressed as
mean ± SEM
Sham I/R I/R + simvastatin
ALT [U/L] 58 ± 10.3 135 ± 14.1 87 ± 13.3
AST [U/L] 152 ± 15.8 335 ± 17.1 231 ± 15.4
LDH [U/L] 1391 ± 172 4558 ± 210 3317 ± 183
TNFa [pg/g tissue] 5.1 ± 1.3 64.7 ± 5.2 41.4 ± 4.1
Table 2. Tissue injury index of the liver and lungs and the number of apoptotic cells 24 h after reperfusion
Sham I/R I/R + simvastatin
Liver injury index 1.1 ± 0.3 18.6 ± 3.6 8.3 ± 2.7
Liver apoptosis 1 ± 0.2 33.4 ± 5.2 18.1 ± 3.4
Lung injury index 0.8 ± 0.3 16.9 ± 3.1 10.3 ± 2.4
Lung apoptosis 1.3 ± 0.2 40.4 ± 8.3 21.3 ± 6.2
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inflammation, hepatic and lung tissue necrosis and
apoptosis.
Although liver I/R is more commonly induced by
occluding the hepatic artery and portal vein to the
left and median liver lobes (60–70% partial liver is-
chaemia) in animal models according to previously
published reports, temporary occlusion of the hepa-
toduodenal ligament (the Pringle manoeuvre) is
more often used in major liver surgery, including liver
transplantation [1]. In the present study we mim-
icked this model, in which hepatic I/R injury induced
by totally occluding the portal vein and hepatic ar-
tery caused more serious damage to livers than the
partial liver ischaemia in our other report [32], sup-
ported by the comparison of the activities of AST
and ALT, and the histological alterations [11]. The
more severe damage to the liver in turn produces
and releases more destructive proinflammatory cy-
tokines into the circulation, such as TNFa and oxy-
gen-derived radicals, causing subsequent damage
to other organs, including the kidney, lung, and in-
testine [14].
In the liver I/R induces inflammatory mediators
such as chemokines, cytokines, and adhesion mole-
cules. These mediators are thought to initiate the
inflammatory cascade that leads to leukocyte recruit-
ment and microcirculatory compromise, with result-
ant liver dysfunction.
Hepatocyte cells that are lethally injured after
ischaemic or toxic insults can die by necrosis or apo-
ptosis. Contrary to apoptosis, which is a well co-
-ordinated process, necrosis usually results from over-
whelming cellular ATP depletion that is beyond re-
pair, and has been known to be an unregulated
event. However, recent studies suggest that necro-
sis is also controlled by a specific programme that
involves many signalling cascades such as reactive
oxygen species and stress kinases [31].
Statins reduce cell adhesion by blocking expres-
sion of monocyte chemotactic protein-1 [4]. They
also inhibit both expression and activation of inte-
grin, which is essential for leukocyte adhesion [20].
Other research has indicated that statins interfere
with the expression of intercellular adhesion mole-
cule-1 (ICAM-1) and cytokines in endothelial cells and
monocytes [26]. Another consequence of the inhibi-
tion of geranylgeranylation of Rho GTPase by statins
is increased expression and activity of eNOS. The re-
sultant increase in nitric oxide production causes re-
duced expression of adhesion molecules, including
selectins and ICAM-1 [29]. The above-mentioned
anti-inflammatory mechanisms of statins are likely
to be responsible for the protective effect of simv-
astatin that we observed in the inhibition of TNFa
production in this rat model of hepatic I/R.
In summary, simvastatin pretreatment protects
the liver and lungs from warm hepatic I/R injury
through multiple pathways, and inhibits cell apo-
ptosis, decreased cellular necrosis and TNFa pro-
duction.
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